Mode
Text Size
Log in / Sign up
N/A N=78

Completion of OST - a Prospective Study

Opioid Dependence

Enrolled (actual)
78
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Completion of OST — 9 participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Opiate Substitution Treatment (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Primary completion
Feb 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Completion of OST
9
PRIMARY
OST Drop-outs
15
SECONDARY
Mean Time to Complete OST
232
SECONDARY
Mean Time to Drop-out of OST
315
SECONDARY
Mean Time Staying in OST
549

Summary

Only limited information on the process of completing long-term opiate substitution treatment (OST) with substances like methadone exist. Furthermore, systematic knowledge from scientific studies is scarce, there are only few studies with respect to treatment completion or regular termination (mainly catamnestic analyses). Studies by Nordt et al. (2004) or Nordt & Stohler (2006) show an estimated rate of 10% of patients per year who terminate OST by means of tapering the substitution agent or changing into withdrawal treatment in specialized clinics. It is state of the art that an indication for termination of OST has to be based on a common agreement between the patient and the doctor. Furthermore, the patient should live in a stable social situation and the state of health had markedly improved. Finally, the patient has to be free of (illegal) drug use for at least 6 months and the individual aims of treatment should have been reached (Vader et al. 2003). The main objective of the prospective and explorative study is the systematic description of the process of termination of OST. With a comparison between patients who complete OST regularly and patients who terminate treatment prematurely (or are still in treatment) predictors of positive termination of OST can be identified. Patients treated with methadone or levomethadone of 5 general practitioners' practices and 2 specialized clinics who might be able to terminate OST during the next 12 months from the doctors' perspective can take part in the study. In addition to baseline examination further assessments take place every 3 months (i.e. after 3, 6, 9 and 12 months). The questionnaires include state of health, well-being, social situation as well as drug and alcohol use. Furthermore, the treating doctors are asked every 3 months to fill out questionnaires on infections and other disorders, clinical characteristics, dosage process and drug use (measured by urine samples). Patients who will be successful in completing OST during the observational period will be compared with the remaining cases. Finally, a 6-month follow-up is planned in order to investigate the stability and maintenance of the situation at month 12.

Eligibility Criteria

Inclusion Criteria

  • opioid dependence according ICD-10
  • Minimum age of 18 years
  • In OST with methadone or levomethadone
  • Expected or planned treatment completion during the next 12 months
  • Informed consent to participate in the study

Exclusion Criteria

  • Patients with planned hospitalisation during the next 12 months
  • Patients who are likely or it is save to assume that they will be incarcerated or imprisoned during the next 12 months
  • Disability to take part in the study or follow the study conditions
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01722435). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search